A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme
- Determine the activity of ZD 1839 in patients with glioblastoma multiforme in first
- Determine the pharmacokinetics and toxicity of this drug in these patients.
- Assess the relationship between epidermal growth factor receptor status in these
patients and activity of this drug.
OUTLINE: Patients receive oral ZD 1839 once daily. Courses repeat every 28 days in the
absence of disease progression or unacceptable toxicity.
Patients are followed for at least 6 months.
PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study within 12-18
Primary Purpose: Treatment
Henry S. Friedman, MD
United States: Federal Government
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|